Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 2Completed 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasms 1

Interventions

Specimen Handling 336Magnetic Resonance Spectroscopy 332Radiotherapy 314Cyclophosphamide 296pembrolizumab 283Cisplatin 266Carboplatin 246Drug Therapy 237Blood Specimen Collection 233Biopsy 205Bevacizumab 188Gemcitabine 176venetoclax 171Radiosurgery 169Capecitabine 165Oxaliplatin 163fludarabine 160Paclitaxel 156Nivolumab 156Standard of Care 138Surveys and Questionnaires 131Surgical Procedures, Operative 131Dexamethasone 126Fluorouracil 125Docetaxel 113tislelizumab 110Rituximab 110Cytarabine 104atezolizumab 101Azacitidine 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × OTHER × lirilumab × Clear all
NCT02813135 2026-01-16

ESMART

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1/2 Recruiting
472 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡